Renal Safety of Hydroxyethyl starch 130/0.42 After Cardiac Surgery: A Retrospective Cohort Analysis

被引:3
|
作者
Morath, Benedict [1 ,2 ,3 ]
Meid, Andreas D. [1 ]
Rickmann, Johannes [4 ]
Soethoff, Jasmin [5 ]
Verch, Markus [5 ]
Karck, Matthias [5 ]
Zaradzki, Marcin [5 ]
机构
[1] Heidelberg Univ Hosp, Dept Clin Pharmacol & Pharmacoepidemiol, Heidelberg, Germany
[2] Heidelberg Univ, Cooperat Unit Clin Pharm, Heidelberg, Germany
[3] Heidelberg Univ Hosp, Hosp Pharm, Heidelberg, Germany
[4] Heidelberg Univ Hosp, Ctr Informat & Med Technol, Heidelberg, Germany
[5] Univ Hosp Heidelberg, Dept Cardiac Surg, Heidelberg, Germany
关键词
ACUTE KIDNEY INJURY; INFLAMMATORY RESPONSE SYNDROME; FLUID RESUSCITATION; SURGICAL-PATIENTS; SALINE; PATHOPHYSIOLOGY; CRYSTALLOIDS; MANAGEMENT; MORTALITY; COLLOIDS;
D O I
10.1007/s40264-021-01116-5
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Introduction The risk for renal complications from hydroxyethyl starch 130/0.42 (HES) impacts treatment decisions in patients after cardiac surgery. Objective The objective of this study was to determine the impact of postoperatively administered HES on renal function and 90-day mortality compared to sole crystalloid administration in patients after elective cardiac surgery. Methods Using electronic health records from a university hospital, confounding-adjusted models analyzed the associations between postoperative HES administration and the occurrence of postoperative acute kidney injury. In addition, 90-day mortality was evaluated. The impact of HES dosage and timing on renal function on trajectories of estimated glomerular filtration rates over the postoperative period was investigated using linear mixed-effects models. Results Overall 1009 patients (45.0%) experienced acute kidney injury. Less acute kidney injury occurred in patients receiving HES compared with patients receiving only crystalloids for fluid resuscitation (43.7% vs 51.2%, p = 0.008). In multivariate acute kidney injury models, HES had a protective association (odds ratio: 0.89; 95% confidence interval 0.82-0.96). Crystalloids were not as protective as HES (odds ratio: 0.98; 95% confidence interval 0.95-1.00). There was no association between HES and 90-day mortality (odds ratio: 1.05; 95% confidence interval 0.88-1.25). Renal function trajectories were dose dependent and biphasic, HES appeared to slow down the late postoperative decline. Conclusions This study showed no association between HES and the postoperative occurrence of acute kidney injury and thus further closes the evidence gap on HES safety in cardiac surgery patients. Although this was a retrospective cohort study, the results indicated that HES might be safely administered to cardiac surgery patients with regard to renal outcomes, especially if it was administered early and dosed appropriately.
引用
收藏
页码:1311 / 1321
页数:11
相关论文
共 50 条
  • [1] Renal Safety of Hydroxyethyl starch 130/0.42 After Cardiac Surgery: A Retrospective Cohort Analysis
    Benedict Morath
    Andreas D. Meid
    Johannes Rickmann
    Jasmin Soethoff
    Markus Verch
    Matthias Karck
    Marcin Zaradzki
    Drug Safety, 2021, 44 : 1311 - 1321
  • [2] Assessing the renal safety of hydroxyethyl starch 130/0.4 in paediatric cardiac patients
    Xue, F. S.
    Liu, Q.
    Wen, C.
    ANAESTHESIA, 2018, 73 (05) : 650 - 651
  • [3] The impact of 30 ml/kg hydroxyethyl starch 130/0.4 vs hydroxyethyl starch 130/0.42 on coagulation in patients undergoing abdominal surgery
    Staikou, Chryssoula
    Paraskeva, Anteia
    Fassoulaki, Argyro
    INDIAN JOURNAL OF MEDICAL RESEARCH, 2012, 136 (03) : 445 - 450
  • [4] Hydroxyethyl starch 130/0.4: Safe in cardiac surgery?
    Davidson, Ingemar J.
    CRITICAL CARE MEDICINE, 2008, 36 (05) : 1695 - 1696
  • [5] Hydroxyethyl starch 200/0.5 induces more renal macrophage infiltration than hydroxyethyl starch 130/0.42 in an isolated renal perfusion model
    L Hüter
    T Simon
    L Weinmann
    G Marx
    Critical Care, 12 (Suppl 2):
  • [6] Bioequivalence comparison between hydroxyethyl starch 130/0.42/6: 1 and hydroxyethyl starch 130/0.4/9: 1
    Lehmann G.
    Marx G.
    Förster H.
    Drugs in R & D, 2007, 8 (4) : 229 - 240
  • [7] Hydroxyethyl starch 130/0.4: Safe in cardiac surgery? Reply
    Boldt, Joachim
    CRITICAL CARE MEDICINE, 2008, 36 (05) : 1696 - 1696
  • [8] In vitro effect of hydroxyethyl starch 130/0.42 on canine platelet function
    Classen, Janine
    Adamik, Katja N.
    Weber, Karin
    Rubenbauer, Stephanie
    Hartmann, Katrin
    AMERICAN JOURNAL OF VETERINARY RESEARCH, 2012, 73 (12) : 1908 - 1912
  • [9] Acute kidney injury with hydroxyethyl starch 130/0.42 in severe sepsis
    Mueller, R. B.
    Haase, N.
    Lange, T.
    Wetterslev, J.
    Perner, A.
    ACTA ANAESTHESIOLOGICA SCANDINAVICA, 2015, 59 (03) : 329 - 336
  • [10] Impact of 6% hydroxyethyl starch 130/0.42 and 4% gelatin on renal function in a pediatric animal model
    Witt, Lars
    Glage, Silke
    Schulz, Katharina
    Lichtinghagen, Ralf
    Simann, Arne
    Pape, Lars
    Suempelmann, Robert
    PEDIATRIC ANESTHESIA, 2014, 24 (09) : 974 - 979